HUTCHMED (LSE:HCM), the biopharmaceutical company listed on AIM, Nasdaq and the Hong Kong Stock Exchange, said partner AstraZeneca has filed a New Drug Application with the US Food and Drug Administration for ORPATHYS plus TAGRISSO in a group of lung cancer patients, supported by the global SAFFRON Phase III trial.

What HUTCHMED announced

In an announcement at 07:00 on 29 September 2026, HUTCHMED said that "AstraZeneca has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA")" for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib).

The application covers patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) "whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth Factor receptor ("EGFR") tyrosine kinase inhibitor ("TKI") therapy". The filing was made by AstraZeneca rather than HUTCHMED itself, which is why the headline refers to AstraZeneca's submission.

The SAFFRON trial behind the filing

HUTCHMED said the NDA is supported by the global SAFFRON Phase III trial, a randomised, open-label study in 338 patients across 230 centres in 29 countries. According to the company, SAFFRON showed the combination "demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival ("PFS") and overall survival ("OS") versus doublet platinum-based chemotherapy in patients who progressed on treatment with TAGRISSO".

The announcement also refers to the Phase II SAVANNAH study, which identified the MET level cut-offs used to select patients for SAFFRON, and to the Phase III SACHI trial, which supported the combination's approval in China. The announcement did not give hazard ratios or median survival figures.

Why the filing matters for HUTCHMED

The US is a large market for lung cancer treatments, and an FDA filing is a step towards possible approval there. HUTCHMED said the combination has already been approved in China and has received temporary authorisation in Switzerland. AstraZeneca is the joint developer and sole commercial partner for ORPATHYS.

Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said: "This filing is an important step toward potentially bringing ORPATHYS® plus TAGRISSO® to patients in the US, after its approval in China based on the SACHI Phase III trial."

The filing follows a busy month of company news. HUTCHMED's recent announcements show that the SANOVO trial "demonstrated significant PFS benefit" (1 September), that it had licensed a KRAS-EGFR antibody to GSK (3 September), and that it had initiated a global trial of HMPL-A830 (28 September).

Commercial and financial context

HUTCHMED did not disclose any milestone payments, Royalty rates or other financial terms tied to the US filing in this announcement. It also did not state whether the FDA has accepted the application for review or give any target decision date. Any financial benefit would depend on regulatory approval and on AstraZeneca's commercial performance in the US.

Risks for investors to consider

A submission is not an approval. The FDA may accept, question or reject the application, and it could ask for more data. Approval, if granted, could come with a narrower label than the one sought. The treatment is aimed at a biomarker-selected group, which depends on MET testing in practice. Competition in EGFR-mutated lung cancer is also intense.

What investors may watch next

Holders of UK shares in HUTCHMED may look for confirmation of FDA acceptance of the NDA and any decision timeline, further SAFFRON data following its presentation at the ESMO Congress 2026, and any updates on other markets. For AIM stocks in biotech, regulatory news of this kind can be a significant driver of sentiment on the London Stock Exchange, although the outcome of the review is not yet known.